We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Lectin-Based Test Estimates Glycated Hemoglobin

By LabMedica International staff writers
Posted on 29 Feb 2012
A novel method has been developed for estimating the glycated hemoglobin (HbA1c) in normal and diabetic patients using a glucose specific lectin. More...


The quantitative precipitin method was performed for the interaction between the glucose-specific lectin Concanavalin A (Con A) and the glucose-containing RBC-lysate for the estimation of calculated HbA1c% from a standard curve.

Scientists at the Cancer Centre Welfare Home and Research Institute, (Kolkata, West Bengal, India) selected 16 patients of both sexes with type-2 diabetes, age range 35–60 years, and four patients with newly diagnosed type-1 diabetes, age range 15–41 years . Twenty sex-matched normal healthy subjects, age range 33-65 years, were also included as controls. A precipitation test of red cell lysate and Con-A was performed and the precipitate estimated spectrophotometrically at 480 nm. For reference, plasma glucose was estimated from the diabetic and nondiabetic subjects by glucose oxidase method using phenol 4-aminophenazone and HbA1c% were measured by ion-exchange high performance liquid chromatography (HPLC) method with the Bio-Rad D-10 analyzer (BioRad; Hercules, CA, USA).

The absorbance range of the precipitate was 0.14–0.20 in normal subjects and the corresponding calculated HbA1c% along with plasma glucose levels was 4.1%-5.8% and 82-101 mg/dL, respectively. For the diabetic patients, HbA1c results were between 6.3%-12.2%, and the plasma glucose range was 120-292 mg/dL. Similar results were observed for HbA1c% (6.1%-11.9%) of the same diabetic samples measured by conventional ion-exchange HPLC. The nondiabetic and diabetic hemoglobin variant subjects consisted of HbE-β-thalassemia, β-thalassemia carrier state, HbE trait, and HbS trait, showed similar HbA1c% by the lectin-based assay when compared with standard HPLC method.

The authors concluded that the lectin-based assay may be adopted to estimate glycated hemoglobin level in differentiating between normal and diabetic patients. This assay offers a good correlation with standard HPLC method, and moreover, the method is convenient, cheap, and needs no sophisticated instruments, and therefore suitable for laboratories in poor resource settings. The study was published online on January 24, 2012, in the Journal of Clinical Laboratory Analysis.

Related Links:

Cancer Centre Welfare Home and Research Institute
BioRad




Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Collection and Transport System
PurSafe Plus®
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Over 100 new epigenetic biomarkers may help predict cardiovascular disease risk (Photo courtesy of 123RF)

Routine Blood Draws Could Detect Epigenetic Biomarkers for Predicting Cardiovascular Disease Risk

Cardiovascular disease is a leading cause of death worldwide, yet predicting individual risk remains a persistent challenge. Traditional risk factors, while useful, do not fully capture biological changes... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.